These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 36470020)

  • 1. Current status and prospects of development of analytical methods for determining nitrosamine and N-nitroso impurities in pharmaceuticals.
    Wichitnithad W; Nantaphol S; Noppakhunsomboon K; Thitikornpong W; Rojsitthisak P
    Talanta; 2023 Mar; 254():124102. PubMed ID: 36470020
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analytical Methodologies to Detect N-Nitrosamine Impurities in Active Pharmaceutical Ingredients, Drug Products and Other Matrices.
    Manchuri KM; Shaik MA; Gopireddy VSR; Naziya Sultana ; Gogineni S
    Chem Res Toxicol; 2024 Sep; 37(9):1456-1483. PubMed ID: 39158368
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An update on the current status and prospects of nitrosation pathways and possible root causes of nitrosamine formation in various pharmaceuticals.
    Wichitnithad W; Nantaphol S; Noppakhunsomboon K; Rojsitthisak P
    Saudi Pharm J; 2023 Feb; 31(2):295-311. PubMed ID: 36942272
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Full Evaporation Static Headspace Gas Chromatography Method with Nitrogen Phosphorous Detection for Ultrasensitive Analysis of Semi-volatile Nitrosamines in Pharmaceutical Products.
    Zheng J; Kirkpatrick CL; Lee D; Han X; Martinez AI; Gallagher K; Evans RK; Mudur SV; Liang X; Drake J; Buhler LA; Mowery MD
    AAPS J; 2022 Jan; 24(1):23. PubMed ID: 34993666
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nitrosamine Impurities in Pharmaceuticals: An Empirical Review of their Detection, Mechanisms, and Regulatory Approaches.
    Bhirud D; Agrawal G; Shah H; Patel A; Palkar MB; Bhattacharya S; Prajapati BG
    Curr Top Med Chem; 2024; 24(6):503-522. PubMed ID: 38321910
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modified NAP test: A simple and Responsive Nitrosating Methodology for Risk Evaluation of NDSRIs.
    Sharma N; Patel R; Bothara T; Jain S; Shah RP
    J Pharm Sci; 2023 May; 112(5):1333-1340. PubMed ID: 36871894
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulatory Updates and Analytical Methodologies for Nitrosamine Impurities Detection in Sartans, Ranitidine, Nizatidine, and Metformin along with Sample Preparation Techniques.
    Shaik KM; Sarmah B; Wadekar GS; Kumar P
    Crit Rev Anal Chem; 2022; 52(1):53-71. PubMed ID: 32691615
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analytical Method Capable of Quantifying Eight Nitrosamine Impurities from Five Different Commercially Available Metformin Formulations with Glipizide, Glibenclamide, Gliclazide, Evogliptin, and Glimepiride by Ultra High Performance Liquid Chromatography Tripple Quadrupole Mass Spectrometry.
    Solanki R; Wadhwana P; Patel R; Gayakvad B; Kothari C; Patel C
    J Pharm Sci; 2023 May; 112(5):1268-1276. PubMed ID: 36822274
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nitrosamines crisis in pharmaceuticals - Insights on toxicological implications, root causes and risk assessment: A systematic review.
    Vikram HPR; Kumar TP; Kumar G; Beeraka NM; Deka R; Suhail SM; Jat S; Bannimath N; Padmanabhan G; Chandan RS; Kumar P; Gurupadayya B
    J Pharm Anal; 2024 May; 14(5):100919. PubMed ID: 38799236
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A GC-MS/MS Method for Trace Level Quantification of Six Nitrosamine Impurities (NDMA, NDEA, NEIPA, NDIPA, NDPA, and NDBA) in Commercially Used Organic Solvents: Dichloromethane, Ethyl Acetate, Toluene, and O-xylene.
    Kosuri ER; Bhanti M; Jaywant MA; Han M; Wang X; Obeng M
    J Pharm Sci; 2023 May; 112(5):1225-1230. PubMed ID: 36462706
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Simultaneous determination of low molecular weight nitrosamines in pharmaceutical products by fast gas chromatography mass spectrometry.
    Kalauz A; Tiringer KV; Horváth V; Kapui I
    J Chromatogr A; 2023 Oct; 1708():464323. PubMed ID: 37696123
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Performance Characteristics of Mass Spectrometry-Based Analytical Procedures for Quantitation of Nitrosamines in Pharmaceuticals: Insights from an Inter-laboratory Study.
    Yang J; Kakarla R; Marzan T; Sherwin B; George M; Bennett J; Basutto J; Su Y; Ollerenshaw J; Morin J; Rebière H; Maggio AF; Kermaïdic A; Gervela E; Brenier C; Civade C; Chauvey D; Duperray F; Wollein U; Conti M; Tromp J; Meyer S; Wanko R; Wierer M; Bertrand M; Rodriguez J; Sommers C; Keire D
    J Pharm Sci; 2023 Oct; 112(10):2685-2695. PubMed ID: 37524228
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation and optimization of a HS-SPME-assisted GC-MS/MS method for monitoring nitrosamine impurities in diverse pharmaceuticals.
    Chang SH; Ho HY; Chang CC; Zang CZ; Hsu YH; Lin MC; Tseng SH; Wang DY
    J Pharm Biomed Anal; 2022 Nov; 221():115003. PubMed ID: 36095885
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Practical and Science-Based Strategy for Establishing Acceptable Intakes for Drug Product
    Dobo KL; Kenyon MO; Dirat O; Engel M; Fleetwood A; Martin M; Mattano S; Musso A; McWilliams JC; Papanikolaou A; Parris P; Whritenour J; Yu S; Kalgutkar AS
    Chem Res Toxicol; 2022 Mar; 35(3):475-489. PubMed ID: 35212515
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comprehensive review of sources of nitrosamine contamination of pharmaceutical substances and products.
    Akkaraju H; Tatia R; Mane SS; Khade AB; Dengale SJ
    Regul Toxicol Pharmacol; 2023 Mar; 139():105355. PubMed ID: 36792049
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulatory Experiences with Root Causes and Risk Factors for Nitrosamine Impurities in Pharmaceuticals.
    Horne S; Vera MD; Nagavelli LR; Sayeed VA; Heckman L; Johnson D; Berger D; Yip YY; Krahn CL; Sizukusa LO; Rocha NFM; Bream RN; Ludwig J; Keire DA; Condran G
    J Pharm Sci; 2023 May; 112(5):1166-1182. PubMed ID: 36599405
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NDSRIs Crisis in Pharmaceuticals; Insights on Formation Pathways, Root Causes, Risk Management, and Novel Analytical Techniques.
    P R HV; Kandula DR; Gunta U; Kumar G; Deka R; Chiriki DS; Chethan KS; Bannimath N; Yadav T; Beeraka NM; Gurupadayya BM
    Curr Med Chem; 2024 Sep; ():. PubMed ID: 39279119
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In Silico Prediction of N-Nitrosamine Formation Pathways of Pharmaceutical Products.
    Tsuji G; Kurohara T; Shoda T; Yokoo H; Ito T; Masada S; Uchiyama N; Yamamoto E; Demizu Y
    Chem Pharm Bull (Tokyo); 2024; 72(2):166-172. PubMed ID: 38296559
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Determining recommended acceptable intake limits for N-nitrosamine impurities in pharmaceuticals: Development and application of the Carcinogenic Potency Categorization Approach (CPCA).
    Kruhlak NL; Schmidt M; Froetschl R; Graber S; Haas B; Horne I; Horne S; King ST; Koval IA; Kumaran G; Langenkamp A; McGovern TJ; Peryea T; Sanh A; Siqueira Ferreira A; van Aerts L; Vespa A; Whomsley R
    Regul Toxicol Pharmacol; 2024 Jun; 150():105640. PubMed ID: 38754805
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nitrosamine Contamination in Pharmaceuticals: Threat, Impact, and Control.
    Tuesuwan B; Vongsutilers V
    J Pharm Sci; 2021 Sep; 110(9):3118-3128. PubMed ID: 33989680
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.